HomeCGEN • NASDAQ
add
Compugen Ltd
Previous close
$2.57
Day range
$2.41 - $2.60
Year range
$1.35 - $3.03
Market cap
225.63M USD
Avg Volume
893.77K
P/E ratio
131.46
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 17.13M | — |
Operating expense | 9.04M | -14.99% |
Net income | 1.28M | 112.95% |
Net profit margin | 7.45 | — |
Earnings per share | 0.01 | 109.09% |
EBITDA | 4.62M | 143.92% |
Effective tax rate | 77.92% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 112.71M | 95.99% |
Total assets | 123.52M | 82.69% |
Total liabilities | 63.03M | 338.18% |
Total equity | 60.49M | — |
Shares outstanding | 89.54M | — |
Price to book | 3.78 | — |
Return on assets | 9.62% | — |
Return on capital | 18.01% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | 1.28M | 112.95% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. Wikipedia
Founded
Feb 10, 1993
Website
Employees
68
